02.29.2024 Vaccines Vaccines Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults 02.26.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.19.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 02.15.2024 Financial Finance Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day 02.12.2024 Corporate Partnerships UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies 02.05.2024 Prescription Medicines Responsibility Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
01.30.2024 Corporate Financial Finance Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance 01.26.2024 Prescription Medicines Medicines European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer 01.10.2024 Financial Finance Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation 01.09.2024 Prescription Medicines Medicines TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer 01.08.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer 01.02.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Frequently Visited Topics
Learn more about Pfizer
Explore some of the most frequently visited pages on our site.
Events and Presentations
Our Areas of Focus
Explore Our Products
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.